The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Trial-in-progress: a Phase II trial investigating liso-cel for eradicating MRD in patients with LBCL
In this video, Dai Chihara, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly shares insight into an investigator-initiated Phase II trial (NCT07316010) that will evaluate lisocabtagene maraleucel (liso-cel) for eradicating measurable residual disease (MRD) in patients with large B-cell lymphoma (LBCL) who have detectable circulating tumor (ct) DNA at the end of first line treatment, aiming to determine whether earlier intervention can improve patient outcomes. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I have a poster, a Trial in Progress, looking at lisocabtagene maraleucel for MRD erasure. I think the field is now very interested in how to utilize the ctDNA MRD information for treatment decision making. It’s one of the very first trials. It is also an investigator-initiated trial, but it’s one of the first studies looking at like early intervention...
I have a poster, a Trial in Progress, looking at lisocabtagene maraleucel for MRD erasure. I think the field is now very interested in how to utilize the ctDNA MRD information for treatment decision making. It’s one of the very first trials. It is also an investigator-initiated trial, but it’s one of the first studies looking at like early intervention. Can early intervention potentially change the outcome of a patient? Can we cure more patients by using the active agents sooner? And we have five centers participating in the study and we’re planning to treat 50 patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
